Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly

September 11, 2023 0

Crinetics Pharmaceuticals Once Daily, Oral Treatment for Acromegaly Crinetics Pharmaceuticals (CRNX) announced that its oral and …

Alpine Immune Sciences Treating IgA Nephropathy Among Other Diseases

August 31, 2023 0

Alpine Immune Sciences Treating IgA nephropathy Alpine Immune Sciences (ALPN) announced a successful initiation of the …

Halozyme Therapeutics ENHANZE Reduces Roche’s Tecentriq® Treatment Time to 7 Minutes from 30-60

August 29, 2023 0

Halozyme Therapeutics in the NEWS Halozyme Therapeutics (HALO) announced today that the Medicines and Healthcare Products …

Exelixis Positive Results in Phase 3 CABINET Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

August 26, 2023 0

Exelixis in the NEWS Exelixis CABOMETYX is approved for the treatment of many cancers. The product …

Arcus Biosciences Participates in Multiple Upcoming Investor Conferences. The Stock is Boosted. See Also: Today’s Roche Press Release

August 23, 2023 0

Arcus Biosciences Arcus Biosciences (RCUS) is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination …

Regeneron Pharmaceuticals EYLEA HD Approved by FDA for Wet Age-related Macular Degeneration, Diabetic Macular Edema and Diabetic Retinopathy

August 21, 2023 0

Regeneron Pharmaceuticals EYLEA HD Approved by the FDA Regeneron Pharmaceuticals (REGN) announced that the U.S. FDA has …

The Biotechnology Revolution: News from Nuvectis Pharma and Revolution Medicines Publication

August 20, 2023 0

Nuvectis Pharma Nuvectis Pharma (NVCT) is a biopharmaceutical company focused on developing innovative precision targeted drugs …

The U.S. FDA Approved Johnson & Johnson AKEEGA™ for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

August 15, 2023 0

Johnson & Johnson’s Janssen Pharmaceutical AKEEGA Johnson & Johnson (JNJ) owned Janssen Pharmaceutical announced that the U.S. …

Xenon Pharmaceuticals Reports 2Q 2023 Financial Results and Provides Corporate Update

August 15, 2023 0

Xenon Pharmaceuticals Q2 Financial Results On August 09, 2023 , Xenon Pharmaceuticals (XENE) reported financial results for …

Reminders About CymaBay Therapeutics and Jazz Pharmaceuticals Conference Calls Today at 4.30 PM

August 10, 2023 0

CymaBay Therapeutics and Jazz Pharmaceuticals Conference Call Info CymaBay Therapeutics: Hosting a Conference Call and Live …

TG Therapeutics Will Have An Important Conference Call at 8:30 AM Tomorrow, August 1st

July 31, 2023 0

TG Therapeutics Conference Call TG Therapeutics (TGTX) announced that, tomorrow, Tuesday, August 1, 2023, a conference …

ImmunoGen Reports Recent Progress and 2Q 2023 Financial Results. In Other News, Anna Berkenblit, MD, Senior VP and CMO Stepping Down from Her Position

July 31, 2023 0

ImmunoGen in the News WALTHAM, Mass.--(BUSINESS WIRE) --Jul. 31, 2023-- ImmunoGen (IMGN), a leader in the …

Merck and Moderna Initiated Phase 3 Study Evaluating V940 in Combination with KEYTRUDA® for Patients with Resected High-Risk Melanoma

July 26, 2023 0

Merck and Moderna Inc Announcement Merck (MRK) and Moderna Inc (MRNA . . . This content …

Why Syndax and Incyte Traded UP in Today’s Early Morning

July 24, 2023 0

Syndax Pharmaceuticals and Incyte Syndax Pharmaceuticals (SNDX) and Incyte (INCY) announced positive data from the pivotal …

Halozyme Therapeutics’ Positive Results for Patients with Chronic Inflammatory Demyelinating Polyneuropathy

July 21, 2023 0

The way drugs are being delivered into patients’ bodies have become more than ever considered important …

Treating Cancers Resistant to ALL Drugs a Priority for Researchers. See What Merck and Kintara Have Done

July 20, 2023 0

Merck and Kintara in the NEWS Treating cancers that have no treatments should be a priority …

Treatments for Untreatable Diseases

July 16, 2023 0

Prohost Letter #456 Treatments for Untreatable Diseases The revolution in biotechnology is not meant to offer …

The U.S. FDA Approved BioMarin’s ROCTAVIANTM, the First and Only Gene Therapy for Adults with Severe Hemophilia A in the US

July 6, 2023 0

BioMarin Pharmaceutical US FDA Approval for ROCTAVIAN On June 30, 2023, BioMarin Pharmaceutical (BMRN) announced that …

The U.S.FDA Granted CellTrans Inc., Approval of its Product Lantidra for the Treatment of Type 1 Diabetes

June 30, 2023 0

CellTrans Inc FDA Approval for Lantidra for Type 1 Diabetes The U.S. Food and Drug Administration …

The U.S. FDA Approved BioMarin Pharmaceutical’s ROCTAVIAN, the First and Only Gene Therapy for Adults with Severe Hemophilia A

June 30, 2023 0

BioMarin Pharmaceutical US FDA Approved ROCTAVIAN BioMarin Pharmaceutical (BMRN) announced that the U.S. FDA approved ROCTAVIAN …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly

Alpine Immune Sciences Treating IgA Nephropathy Among Other Diseases

Halozyme Therapeutics ENHANZE Reduces Roche’s Tecentriq® Treatment Time to 7 Minutes from 30-60

Exelixis Positive Results in Phase 3 CABINET Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Arcus Biosciences Participates in Multiple Upcoming Investor Conferences. The Stock is Boosted. See Also: Today’s Roche Press Release

Regeneron Pharmaceuticals EYLEA HD Approved by FDA for Wet Age-related Macular Degeneration, Diabetic Macular Edema and Diabetic Retinopathy

The Biotechnology Revolution: News from Nuvectis Pharma and Revolution Medicines Publication

The U.S. FDA Approved Johnson & Johnson AKEEGA™ for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Xenon Pharmaceuticals Reports 2Q 2023 Financial Results and Provides Corporate Update

Reminders About CymaBay Therapeutics and Jazz Pharmaceuticals Conference Calls Today at 4.30 PM

TG Therapeutics Will Have An Important Conference Call at 8:30 AM Tomorrow, August 1st

ImmunoGen Reports Recent Progress and 2Q 2023 Financial Results. In Other News, Anna Berkenblit, MD, Senior VP and CMO Stepping Down from Her Position

Merck and Moderna Initiated Phase 3 Study Evaluating V940 in Combination with KEYTRUDA® for Patients with Resected High-Risk Melanoma

Why Syndax and Incyte Traded UP in Today’s Early Morning

Halozyme Therapeutics’ Positive Results for Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Treating Cancers Resistant to ALL Drugs a Priority for Researchers. See What Merck and Kintara Have Done

Treatments for Untreatable Diseases

The U.S. FDA Approved BioMarin’s ROCTAVIANTM, the First and Only Gene Therapy for Adults with Severe Hemophilia A in the US

The U.S.FDA Granted CellTrans Inc., Approval of its Product Lantidra for the Treatment of Type 1 Diabetes

The U.S. FDA Approved BioMarin Pharmaceutical’s ROCTAVIAN, the First and Only Gene Therapy for Adults with Severe Hemophilia A